F
Fibrocell Science
Home - Fibrocell : Fibrocell
About Fibrocell Science
Castle Creek Biosciences, Inc., based in Exton, PA, specializes in developing and commercializing personalized gene therapies aimed at treating rare and serious genetic diseases. The company operates in the biotechnology sector, focusing on patients with unmet medical needs. Its proprietary platform technology and manufacturing expertise enable the creation of transformative gene therapies. Castle Creek Biosciences primarily serves patients suffering from conditions such as dystrophic epidermolysis bullosa, a rare genetic disorder. The business model revolves around research and development, clinical trials, and eventual commercialization of these therapies. Revenue is generated through the sale of these specialized treatments, often in collaboration with healthcare providers and research institutions. The company is a portfolio entity of Paragon Biosciences, which supports its mission to improve patient outcomes through innovative medical solutions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1995
- Headquarters
- West Whiteland Township, United States
- Listing
- IPO 2009
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 25.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2019 | $63M | $63M | Castle Creek Biosciences | ↗ |
| POST IPO EQUITY✓Other financing | Dec 2017 | $11M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $492K | 0% |
| 2025 | $492K | 0% |
| 2024 | $492K | 0% |
| 2023 | $492K | 0% |
| 2022 | $492K | 0% |
| 2021 | $492K | 0% |
| 2020 | $492K | — |
Growth signals
Latest recorded traffic for Fibrocell Science is 0 monthly website visits. Fibrocell Science's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Castle Creek Biosciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fibrocell Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fibrocell Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.